Neal Walker's most recent trade in Aldeyra Therapeutics Inc was a trade of 70,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 09 Jun 2026 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | ||
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 09 Jun 2026 | 3,318 | 3,318 | - | - | Stock Option (Right to Buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | 03 Feb 2026 | 63,475 | 190,425 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 63,475 | 1,562,497 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 63,475 | 1,562,497 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 03 Feb 2026 | 18,611 | 1,543,886 (3%) | 0% | 3.5 | 64,580 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 03 Feb 2026 | 18,611 | 1,543,886 (3%) | 0% | 3.5 | 64,580 | - |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | 02 Feb 2026 | 961,700 | 961,700 | - | - | Employee Stock Option (Right to Buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | 02 Feb 2026 | 274,800 | 274,800 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 29,150 | 1,508,974 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | 02 Jan 2026 | 29,150 | 30,034 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 29,150 | 1,508,974 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 02 Jan 2026 | 9,952 | 1,499,022 (3%) | 0% | 2.9 | 28,662 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. | 02 Jan 2026 | 9,952 | 1,499,022 (3%) | 0% | 2.9 | 28,662 | - |
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 10 Jun 2025 | 62,728 | 62,728 | - | - | Stock Option (Right to Buy) | ||
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 10 Jun 2025 | 2,413 | 2,413 | - | - | Stock Option (Right to Buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | 01 May 2025 | 9,467 | 0 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 9,467 | 1,482,799 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 9,467 | 1,482,799 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.38 per share. | 01 May 2025 | 2,975 | 1,479,824 (3%) | 0% | 1.4 | 4,106 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.38 per share. | 01 May 2025 | 2,975 | 1,479,824 (3%) | 0% | 1.4 | 4,106 | - |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 9,467 | 1,476,374 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | 01 Apr 2025 | 9,467 | 9,467 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 9,467 | 1,476,374 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.48 per share. | 01 Apr 2025 | 3,042 | 1,473,332 (3%) | 0% | 1.5 | 4,502 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.48 per share. | 01 Apr 2025 | 3,042 | 1,473,332 (3%) | 0% | 1.5 | 4,502 | - |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | 01 Mar 2025 | 9,466 | 18,934 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 9,466 | 1,470,184 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 9,466 | 1,470,184 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.99 per share. | 01 Mar 2025 | 3,277 | 1,466,907 (3%) | 0% | 2.0 | 6,521 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.99 per share. | 01 Mar 2025 | 3,277 | 1,466,907 (3%) | 0% | 2.0 | 6,521 | - |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 01 Feb 2025 | 888,800 | 888,800 | - | - | Employee Stock Option (Right to Buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 01 Feb 2025 | 253,900 | 253,900 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 9,467 | 1,464,277 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 01 Feb 2025 | 9,467 | 28,400 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 9,467 | 1,464,277 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 3,559 | 1,460,718 (3%) | 0% | 2.5 | 8,826 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 3,559 | 1,460,718 (3%) | 0% | 2.5 | 8,826 | - |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 01 Jan 2025 | 88,333 | 88,333 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 29,149 | 1,468,342 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 01 Jan 2025 | 29,149 | 59,184 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 29,149 | 1,468,342 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Jan 2025 | 13,532 | 1,454,810 (3%) | 0% | 2.5 | 33,559 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Jan 2025 | 13,532 | 1,454,810 (3%) | 0% | 2.5 | 33,559 | - |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 9,467 | 1,443,097 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 01 Jan 2025 | 9,467 | 37,867 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 9,467 | 1,443,097 (3%) | 0% | - | - | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Jan 2025 | 3,904 | 1,439,193 (3%) | 0% | 2.5 | 9,682 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Jan 2025 | 3,904 | 1,439,193 (3%) | 0% | 2.5 | 9,682 | - |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 04 Dec 2024 | 118,840 | 0 | - | - | Employee Stock Option (right to buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.52 per share. | 04 Dec 2024 | 118,840 | 1,501,973 (3%) | 0% | 1.5 | 180,637 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. | 04 Dec 2024 | 68,343 | 1,433,630 (3%) | 0% | 3.8 | 256,970 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | 01 Dec 2024 | 9,466 | 47,334 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 9,466 | 1,385,854 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.07 per share. | 01 Dec 2024 | 2,721 | 1,383,133 (3%) | 0% | 4.1 | 11,074 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 Nov 2024 | 9,467 | 56,800 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,467 | 1,379,109 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 01 Nov 2024 | 2,721 | 1,376,388 (3%) | 0% | 2.1 | 5,687 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 9,467 | 1,372,364 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 Oct 2024 | 9,467 | 66,267 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 01 Oct 2024 | 2,722 | 1,369,642 (3%) | 0% | 1.2 | 3,212 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 9,466 | 1,365,619 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 Sep 2024 | 9,466 | 75,734 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.18 per share. | 01 Sep 2024 | 2,722 | 1,362,897 (3%) | 0% | 1.2 | 3,212 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.72 per share. | 09 Aug 2024 | 43,548 | 1,356,153 (3%) | 0% | 0.7 | 31,355 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 09 Aug 2024 | 43,548 | 0 | - | - | Employee Stock Option (right to buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 Aug 2024 | 9,467 | 85,200 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 9,467 | 1,315,327 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.32 per share. | 01 Aug 2024 | 2,722 | 1,312,605 (3%) | 0% | 1.3 | 3,593 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 Jul 2024 | 9,467 | 94,667 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 9,467 | 1,308,582 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 01 Jul 2024 | 2,722 | 1,305,860 (3%) | 0% | 1.1 | 3,130 | Common Stock |
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 04 Jun 2024 | 40,282 | 40,282 | - | - | Stock Option (Right to Buy) | ||
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 04 Jun 2024 | 1,736 | 1,736 | - | - | Stock Option (Right to Buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 9,466 | 1,301,837 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 Jun 2024 | 9,466 | 104,134 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.03 per share. | 01 Jun 2024 | 2,722 | 1,299,115 (3%) | 0% | 1.0 | 2,804 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 May 2024 | 9,467 | 113,600 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 9,467 | 1,295,155 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 01 May 2024 | 2,784 | 1,292,371 (3%) | 0% | 1.3 | 3,508 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 9,467 | 1,288,912 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | 01 Apr 2024 | 9,467 | 123,067 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, INTERIM PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 01 Apr 2024 | 3,224 | 1,285,688 (3%) | 0% | 1.3 | 4,062 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, Interim President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 9,466 | 1,282,668 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, Interim President and CEO | 01 Mar 2024 | 9,466 | 132,534 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, Interim President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 3,223 | 1,279,445 (3%) | 0% | 1.2 | 3,997 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, Interim CEO | 01 Feb 2024 | 497,000 | 497,000 | - | - | Stock Option (Right to Buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director, Interim CEO | 01 Feb 2024 | 142,000 | 142,000 | - | - | Restricted Stock Units | ||
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.55 per share. | 22 Aug 2023 | 9,604 | 15,854 (0%) | 0% | 0.6 | 5,301 | Common Stock |
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 22 Aug 2023 | 9,604 | 0 | - | - | Stock Option (Right to Buy) | ||
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 30 Jun 2023 | 21,222 | 21,222 | - | - | Stock Option (Right to Buy) | ||
| Aldeyra Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 30 Jun 2023 | 915 | 915 | - | - | Stock Option (Right to Buy) | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 96,150 | 1,271,913 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 01 Mar 2023 | 96,150 | 0 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | Sale of securities on an exchange or to another person at price $ 12.63 per share. | 01 Mar 2023 | 30,240 | 1,273,202 (3%) | 0% | 12.6 | 382,070 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | Sale of securities on an exchange or to another person at price $ 12.37 per share. | 01 Mar 2023 | 29,000 | 1,285,188 (3%) | 0% | 12.4 | 358,588 | Common Stock |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 01 Mar 2023 | 24,000 | 72,000 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 24,000 | 1,314,188 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 18,275 | 1,290,188 (3%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | 01 Mar 2023 | 18,275 | 36,550 | - | - | Restricted Stock Units | ||
| Aclaris Therapeutics Inc | Dr. Neal Walker, D.O. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 18,254 | 1,303,442 (3%) | 0% | - | Common Stock |